Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?
Stephen J. Nicholls, Jordan Andrews and MyNgan Duong
Pages 649-652 (4)
Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular
(CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding
of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic
strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density
lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and
clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility.
This review will reflect on challenges faced in developing new effective HDL targeted therapies.
Atherosclerosis, high-density lipoproteins, lipids, risk factors.
South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia.